Literature DB >> 21686655

A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib.

Mark Tuthill1, Ravi Barod, Linda Pyle, Terry Cook, Shern Chew, Martin Gore, Patrick Maxwell, Tim Eisen.   

Abstract

UNLABELLED: We report a patient who initially presented with an abdominal paraganglioma and subsequently metastatic papillary cell renal cancer. Genetic analysis revealed a 141 G>A (exon 2) Trp47X mutation within the succinate dehydrogenase B gene. Treatment with the novel multi-targeted tyrosine kinase inhibitor sunitinib resulted in a sustained partial response and reduced the level of the angiogenic marker PIGF. TRIAL REGISTRATION NUMBER: a6181037.

Entities:  

Year:  2009        PMID： 21686655      PMCID： PMC3028009          DOI： 10.1136/bcr.08.2008.0732

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  18 in total

1.  Sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Brian I Rini; Ronald M Bukowski; Brendan D Curti; Daniel J George; Gary R Hudes; Bruce G Redman; Kim A Margolin; Jaime R Merchan; George Wilding; Michelle S Ginsberg; Jennifer Bacik; Sindy T Kim; Charles M Baum; M Dror Michaelson
Journal:  JAMA       Date:  2006-06-07       Impact factor: 56.272

2.  A molecular classification of papillary renal cell carcinoma.

Authors:  Ximing J Yang; Min-Han Tan; Hyung L Kim; Jonathon A Ditlev; Mark W Betten; Carolina E Png; Eric J Kort; Kunihiko Futami; Kyle A Furge; Masayuki Takahashi; Hiro-Omi Kanayama; Puay Hoon Tan; Bin Sing Teh; Chunyan Luan; Kim Wang; Michael Pins; Maria Tretiakova; John Anema; Richard Kahnoski; Theresa Nicol; Walter Stadler; Nicholas G Vogelzang; Robert Amato; David Seligson; Robert Figlin; Arie Belldegrun; Craig G Rogers; Bin Tean Teh
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.

Authors:  S Negrier; B Escudier; C Lasset; J Y Douillard; J Savary; C Chevreau; A Ravaud; A Mercatello; J Peny; M Mousseau; T Philip; T Tursz
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

4.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

5.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase.

Authors:  Mary A Selak; Sean M Armour; Elaine D MacKenzie; Houda Boulahbel; David G Watson; Kyle D Mansfield; Yi Pan; M Celeste Simon; Craig B Thompson; Eyal Gottlieb
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

6.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

7.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations.

Authors:  Hartmut P H Neumann; Christian Pawlu; Mariola Peczkowska; Birke Bausch; Sarah R McWhinney; Mihaela Muresan; Mary Buchta; Gerlind Franke; Joachim Klisch; Thorsten A Bley; Stefan Hoegerle; Carsten C Boedeker; Giuseppe Opocher; Jörg Schipper; Andrzej Januszewicz; Charis Eng
Journal:  JAMA       Date:  2004-08-25       Impact factor: 56.272

8.  CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas).

Authors:  Anju Sahdev; A Sohaib; John P Monson; Ashley B Grossman; Shern L Chew; Rodney H Reznek
Journal:  Eur Radiol       Date:  2004-07-28       Impact factor: 5.315

9.  Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis.

Authors:  A Takahashi; H Sasaki; S J Kim; K Tobisu; T Kakizoe; T Tsukamoto; Y Kumamoto; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

10.  Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.

Authors:  Jean-Pierre Bayley; Ivonne van Minderhout; Marjan M Weiss; Jeroen C Jansen; Peter H N Oomen; Fred H Menko; Barbara Pasini; Barbara Ferrando; Nora Wong; Lesley C Alpert; Rosie Williams; Edward Blair; Peter Devilee; Peter E M Taschner
Journal:  BMC Med Genet       Date:  2006-01-11       Impact factor: 2.103
View more
  6 in total

1.  Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

Authors:  Judith Favier; Peter Igaz; Nelly Burnichon; Laurence Amar; Rossella Libé; Cécile Badoual; Frédérique Tissier; Jérôme Bertherat; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

2.  Mapping of succinate dehydrogenase losses in 2258 epithelial neoplasms.

Authors:  Markku Miettinen; Maarit Sarlomo-Rikala; Peter McCue; Piotr Czapiewski; Renata Langfort; Piotr Waloszczyk; Krzysztof Wazny; Wojciech Biernat; Jerzy Lasota; Zengfeng Wang
Journal:  Appl Immunohistochem Mol Morphol       Date:  2014-01

3.  [Succinate dehydrogenase (SDH)-deficient renal cell carcinoma].

Authors:  A Agaimy
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

4.  Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients.

Authors:  Anthony J Gill; Ondrej Hes; Thomas Papathomas; Monika Šedivcová; Puay Hoon Tan; Abbas Agaimy; Per Arne Andresen; Andrew Kedziora; Adele Clarkson; Christopher W Toon; Loretta Sioson; Nicole Watson; Angela Chou; Julie Paik; Roderick J Clifton-Bligh; Bruce G Robinson; Diana E Benn; Kirsten Hills; Fiona Maclean; Nicolasine D Niemeijer; Ljiljana Vlatkovic; Arndt Hartmann; Eleonora P M Corssmit; Geert J L H van Leenders; Christopher Przybycin; Jesse K McKenney; Cristina Magi-Galluzzi; Asli Yilmaz; Darryl Yu; Katherine D Nicoll; Jim L Yong; Mathilde Sibony; Evgeny Yakirevich; Stewart Fleming; Chung W Chow; Markku Miettinen; Michal Michal; Kiril Trpkov
Journal:  Am J Surg Pathol       Date:  2014-12       Impact factor: 6.394

5.  SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response.

Authors:  Christopher R McEvoy; Lisa Koe; David Y Choong; Huei San Leong; Huiling Xu; Deme Karikios; Jeffrey D Plew; Owen W Prall; Andrew P Fellowes; Stephen B Fox
Journal:  NPJ Precis Oncol       Date:  2018-03-20

6.  Renal cell carcinoma harboring somatic TSC2 mutations in a child with methylmalonic acidemia.

Authors:  Samara L Potter; Rajkumar Venkatramani; Scott Wenderfer; Brett H Graham; Sanjeev A Vasudevan; Andrew Sher; Hao Wu; David A Wheeler; Yaping Yang; Christine M Eng; Richard A Gibbs; Angshumoy Roy; Sharon E Plon; D Williams Parsons
Journal:  Pediatr Blood Cancer       Date:  2016-10-17       Impact factor: 3.167
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.